Effects of paliperidone extended release on hostility among Thai patients with schizophrenia

Código QR

Effects of paliperidone extended release on hostility among Thai patients with schizophrenia

Apichat Jariyavilas,1 Nuntika Thavichachart,2 Ronnachai Kongsakon,3 Sunanta Chantakarn,4 Suwanna Arunpongpaisal,5 Vasu Chantarasak,6 Piyadit Jaroensook,7 Khanogwan Kittiwattanagul,8 Osot Nerapusee9 1Srithanya Hospital, Department of Mental Health, Ministry of Public Health, Bangkok, 2Department of...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jariyavilas A, Thavichachart N, Kongsakon R, Chantakarn S, Arunpongpaisal S, Chantarasak V, Jaroensook P, Kittiwattanagul K, Nerapusee O
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	Schizophrenia hostility aggression disturbing behavior paliperidone ER Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/24a99dff293c4b2085aed186959b4602
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Psychosocial functioning in schizophrenia: are some symptoms or demographic characteristics predictors across the functioning domains?
por: Suttajit S, et al.
Publicado: (2015)

Treatment satisfaction with paliperidone extended-release tablets: open-label study in schizophrenia patients dissatisfied with previous antipsychotic medication
por: Yang FD, et al.
Publicado: (2017)

Improvement in social and cognitive functioning associated with paliperidone extended-release treatment in patients with schizophrenia: a 24-week, single arm, open-label study
por: Shi C, et al.
Publicado: (2016)

Critical evaluation of paliperidone in the treatment of schizophrenia in Chinese patients: a systematic literature review
por: Zhang LL, et al.
Publicado: (2016)

Comparison of Relapse Prevention with 3 Different Paliperidone Formulations in Patients with Schizophrenia Continuing versus Discontinuing Active Antipsychotic Treatment: A Post-Hoc Analysis of 3 Similarly Designed Randomized Studies
por: Mathews M, et al.
Publicado: (2020)

Effects of asenapine on agitation and hostility in adults with acute manic or mixed episodes associated with bipolar I disorder
por: Citrome L, et al.
Publicado: (2017)

Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review
por: Emsley R, et al.
Publicado: (2018)

Effect of Paliperidone Palmitate 3-Month Formulation on Goal Attainment and Disability After 52 Weeks’ Treatment in Patients with Clinically Stable Schizophrenia
por: Lambert M, et al.
Publicado: (2020)

Treatment of Patients with Recently Exacerbated Schizophrenia with Paliperidone Palmitate: A Pilot Study of Efficacy and Tolerability
por: Gattaz WF, et al.
Publicado: (2020)

Role of 3-monthly long-acting injectable paliperidone in the maintenance of schizophrenia
por: Brasso C, et al.
Publicado: (2017)

Efficacy, tolerability, and safety of oral paliperidone extended release in the treatment of schizophrenia: a 24-week, open-label, prospective switch study in different settings in Taiwan
por: Chen CY, et al.
Publicado: (2018)

Once-monthly paliperidone palmitate in early stage schizophrenia – a retrospective, non-interventional 1-year study of patients with newly diagnosed schizophrenia
por: Emsley R, et al.
Publicado: (2017)

Efficacy and safety of once-monthly injection of paliperidone palmitate in hospitalized Asian patients with acute exacerbated schizophrenia: an open-label, prospective, noncomparative study
por: Li HF, et al.
Publicado: (2015)

Long-term efficacy and safety of paliperidone palmitate once-monthly in Chinese patients with recent-onset schizophrenia
por: Si T, et al.
Publicado: (2019)

Safety and efficacy of paliperidone palmitate 1-month formulation in Chinese patients with schizophrenia: a 25-week, open-label, multicenter, Phase IV study
por: Zhao JP, et al.
Publicado: (2017)

STRUCTURAL ORGANIZATION OF AGGRESSIVENESS IN ADOLESCENTS WITH DIFFERENT LEVELS OF «END-NON-IMPRESSURE» AND «END-UNY»
por: G. Uvarova, et al.
Publicado: (2018)

Online Survey of Clinical Practice in Patients with Schizophrenia Treated with Long-Acting Injectable Aripiprazole or Paliperidone Palmitate
por: Such P, et al.
Publicado: (2021)

INVESTIGATION OF THE ATTITUDE OF SYRIAN REFUGEES IN TERMS OF HOSTILE ATTRIBUTION BIAS
por: Yeliz KINDAP, et al.
Publicado: (2020)

Long-Acting Injectable Drugs in the Maintenance Therapy of Patients with Schizophrenia
por: Natalia N. Petrova, et al.
Publicado: (2020)

Time to onset and time to resolution of extrapyramidal symptoms in patients with exacerbated schizophrenia treated with 3-monthly vs once-monthly paliperidone palmitate
por: Mathews M, et al.
Publicado: (2018)

Engineering cocrystals of Paliperidone with enhanced solubility and dissolution characteristics
por: Radha-Rani Earle, et al.
Publicado: (2021)

Igor A. Fourmanov
por: Igor A. Fourmanov
Publicado: (2020)

Improvement of Negative Symptoms in Schizophrenia with Paliperidone Palmitate 1-Month and 3-Month Long-Acting Injectables: Results from a Phase 3 Non-Inferiority Study
por: Gopal S, et al.
Publicado: (2020)

Algorithmic or Human Source? Examining Relative Hostile Media Effect With a Transformer-Based Framework
por: Chenyan Jia, et al.
Publicado: (2021)

Clinical relevance of paliperidone palmitate 3-monthly in treating schizophrenia
por: Mathews M, et al.
Publicado: (2019)

Safety and efficacy of paliperidone extended-release in Chinese patients with schizophrenia: a 24-week, open-label extension of a randomized, double-blind, placebo-controlled study
por: Zhang H, et al.
Publicado: (2016)

METHODS OF PRICE MANIPULATION ON A STOCK MARKET DURING HOSTILE TAKEOVER OF A COMPANY
por: A. Gulyatkin
Publicado: (2016)

Responsible media: Learning to survive the world’s difficult, remote and hostile environments
por: Shaun Filer
Publicado: (2010)

Efficacy and safety of paliperidone palmitate three-monthly formulation in East Asian patients with schizophrenia: subgroup analysis of a global, randomized, double-blind, Phase III, noninferiority study
por: Savitz AJ, et al.
Publicado: (2017)

Effectiveness of 1-year treatment with long-acting formulation of aripiprazole, haloperidol, or paliperidone in patients with schizophrenia: retrospective study in a real-world clinical setting
por: Di Lorenzo R, et al.
Publicado: (2019)

Validation of a quick and simple chromatographic method for simultaneous quantification of sertraline, escitalopram, risperidone and paliperidone levels in the human plasma
por: Jeremić Aleksandra, et al.
Publicado: (2021)

Schizophrenia research and treatment

Schizophrenia research
Publicado: (1988)

An open-label, prospective study to evaluate social function and overall improvement of extended-release paliperidone treatment in Thai schizophrenia patients
por: Charnsil C, et al.
Publicado: (2013)

Clinical schizophrenia & related psychoses
Publicado: (2007)

Head-to-head comparison of 1-year aripiprazole long-acting injectable (LAI) versus paliperidone LAI in comorbid psychosis and substance use disorder: impact on clinical status, substance craving, and quality of life
por: Cuomo I, et al.
Publicado: (2018)

Long-lasting extrapyramidal symptoms after multiple injections of paliperidone palmitate to treat schizophrenia
por: Takada R, et al.
Publicado: (2018)

Social and socio-psychological peculiarities of adolescent aggression in modern Russian society: regional aspect
por: V. V. Levchenko
Publicado: (2020)

Comparison of the two Methods of Storytelling in Decrease of Aggression from ParentsPoint of View
por: R Nasirzadeh,, et al.
Publicado: (2010)

Individual and Interpersonal Factors Associated with the Incidence, Persistence, and Remission of Internet Gaming Disorders Symptoms in an Adolescents Sample
por: Rosario J. Marrero, et al.
Publicado: (2021)